Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sb-649868. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 known ✓ | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 known ✓ | O43614 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-649868 SCHEMBL29424764 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL1398620 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL1398677 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL1398707 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL3638954 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2 | |
| SCHEMBL20827765 | 0.90 | HCRTR1 (0.81) | HCRTR1HCRTR2 | |
| SCHEMBL15173819 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL18734312 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15173821 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15174162 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | claimed |
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | disclosed |
| US-20230270739-A1 | Methods and Compositions for Treating Pain While Minimizing the Risk of Opioid Addiction | UNIV CALIFORNIA (US) | 2023-08-31 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009034133-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885HCRTR2 2/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | HCRTR1 18/4885HCRTR2 14/4885 |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | HLA-DRB1, HLA-C, BRCA1 | HCRTR1 4137/4885HCRTR2 3700/4885 |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | HCRTR1 22/4885HCRTR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.